165 related articles for article (PubMed ID: 37223681)
1. MAP4K4 and cancer: ready for the main stage?
González-Montero J; Rojas CI; Burotto M
Front Oncol; 2023; 13():1162835. PubMed ID: 37223681
[TBL] [Abstract][Full Text] [Related]
2. MAP4K4 promotes pancreatic tumorigenesis via phosphorylation and activation of mixed lineage kinase 3.
Singh SK; Kumar S; Viswakarma N; Principe DR; Das S; Sondarva G; Nair RS; Srivastava P; Sinha SC; Grippo PJ; Thatcher GRJ; Rana B; Rana A
Oncogene; 2021 Oct; 40(43):6153-6165. PubMed ID: 34511598
[TBL] [Abstract][Full Text] [Related]
3. Downregulated miR-98-5p promotes PDAC proliferation and metastasis by reversely regulating MAP4K4.
Fu Y; Liu X; Chen Q; Liu T; Lu C; Yu J; Miao Y; Wei J
J Exp Clin Cancer Res; 2018 Jul; 37(1):130. PubMed ID: 29970191
[TBL] [Abstract][Full Text] [Related]
4. miRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4.
Zhao G; Wang B; Liu Y; Zhang JG; Deng SC; Qin Q; Tian K; Li X; Zhu S; Niu Y; Gong Q; Wang CY
Mol Cancer Ther; 2013 Nov; 12(11):2569-80. PubMed ID: 24013097
[TBL] [Abstract][Full Text] [Related]
5. Map4k4 suppresses Srebp-1 and adipocyte lipogenesis independent of JNK signaling.
Danai LV; Guilherme A; Guntur KV; Straubhaar J; Nicoloro SM; Czech MP
J Lipid Res; 2013 Oct; 54(10):2697-707. PubMed ID: 23924694
[TBL] [Abstract][Full Text] [Related]
6. The Ste20 Family Kinases MAP4K4, MINK1, and TNIK Converge to Regulate Stress-Induced JNK Signaling in Neurons.
Larhammar M; Huntwork-Rodriguez S; Rudhard Y; Sengupta-Ghosh A; Lewcock JW
J Neurosci; 2017 Nov; 37(46):11074-11084. PubMed ID: 28993483
[TBL] [Abstract][Full Text] [Related]
7. The molecular basis of the dichotomous functionality of MAP4K4 in proliferation and cell motility control in cancer.
Jovanovic D; Yan S; Baumgartner M
Front Oncol; 2022; 12():1059513. PubMed ID: 36568222
[TBL] [Abstract][Full Text] [Related]
8. MiR-194, commonly repressed in colorectal cancer, suppresses tumor growth by regulating the MAP4K4/c-Jun/MDM2 signaling pathway.
Wang B; Shen ZL; Gao ZD; Zhao G; Wang CY; Yang Y; Zhang JZ; Yan YC; Shen C; Jiang KW; Ye YJ; Wang S
Cell Cycle; 2015; 14(7):1046-58. PubMed ID: 25602366
[TBL] [Abstract][Full Text] [Related]
9. Silencing SOX2 Expression by RNA Interference Inhibits Proliferation, Invasion and Metastasis, and Induces Apoptosis through MAP4K4/JNK Signaling Pathway in Human Laryngeal Cancer TU212 Cells.
Yang N; Wang Y; Hui L; Li X; Jiang X
J Histochem Cytochem; 2015 Sep; 63(9):721-33. PubMed ID: 26001828
[TBL] [Abstract][Full Text] [Related]
10. A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase.
Collins CS; Hong J; Sapinoso L; Zhou Y; Liu Z; Micklash K; Schultz PG; Hampton GM
Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3775-80. PubMed ID: 16537454
[TBL] [Abstract][Full Text] [Related]
11. RBM4a-SRSF3-MAP4K4 Splicing Cascade Constitutes a Molecular Mechanism for Regulating Brown Adipogenesis.
Peng HY; Liang YC; Tan TH; Chuang HC; Lin YJ; Lin JC
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30200638
[TBL] [Abstract][Full Text] [Related]
12. Molecular Insights of MAP4K4 Signaling in Inflammatory and Malignant Diseases.
Singh SK; Roy R; Kumar S; Srivastava P; Jha S; Rana B; Rana A
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190200
[TBL] [Abstract][Full Text] [Related]
13. MAP4K4 promotes epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma.
Feng XJ; Pan Q; Wang SM; Pan YC; Wang Q; Zhang HH; Zhu MH; Zhang SH
Tumour Biol; 2016 Aug; 37(8):11457-67. PubMed ID: 27010469
[TBL] [Abstract][Full Text] [Related]
14. Mitogen-activated protein kinase kinase kinase kinase 4 as a putative effector of Rap2 to activate the c-Jun N-terminal kinase.
Machida N; Umikawa M; Takei K; Sakima N; Myagmar BE; Taira K; Uezato H; Ogawa Y; Kariya K
J Biol Chem; 2004 Apr; 279(16):15711-4. PubMed ID: 14966141
[TBL] [Abstract][Full Text] [Related]
15. Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.
Liang JJ; Wang H; Rashid A; Tan TH; Hwang RF; Hamilton SR; Abbruzzese JL; Evans DB; Wang H
Clin Cancer Res; 2008 Nov; 14(21):7043-9. PubMed ID: 18981001
[TBL] [Abstract][Full Text] [Related]
16. MAP4K4 promotes ovarian cancer metastasis through diminishing ADAM10-dependent N-cadherin cleavage.
Chen K; Yuan X; Wang S; Zheng F; Fu Z; Shen Z; Cheng X; Wang Y; Tang S; Ni H; Wang F; Lu G; Wu Y; Xia D; Lu W
Oncogene; 2023 May; 42(18):1438-1452. PubMed ID: 36922678
[TBL] [Abstract][Full Text] [Related]
17. Identification of Map4k4 as a novel suppressor of skeletal muscle differentiation.
Wang M; Amano SU; Flach RJ; Chawla A; Aouadi M; Czech MP
Mol Cell Biol; 2013 Feb; 33(4):678-87. PubMed ID: 23207904
[TBL] [Abstract][Full Text] [Related]
18. MAP4K4: an emerging therapeutic target in cancer.
Gao X; Gao C; Liu G; Hu J
Cell Biosci; 2016; 6():56. PubMed ID: 27800153
[TBL] [Abstract][Full Text] [Related]
19. Targeted genomic CRISPR-Cas9 screen identifies MAP4K4 as essential for glioblastoma invasion.
Prolo LM; Li A; Owen SF; Parker JJ; Foshay K; Nitta RT; Morgens DW; Bolin S; Wilson CM; Vega L JCM; Luo EJ; Nwagbo G; Waziri A; Li G; Reimer RJ; Bassik MC; Grant GA
Sci Rep; 2019 Sep; 9(1):14020. PubMed ID: 31570734
[TBL] [Abstract][Full Text] [Related]
20. In silico identification and biological evaluation of a selective MAP4K4 inhibitor against pancreatic cancer.
Chang CD; Chao MW; Lee HY; Liu YT; Tu HJ; Lien ST; Lin TE; Sung TY; Yen SC; Huang SH; Hsu KC; Pan SL
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2166039. PubMed ID: 36683274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
